2135696-72-7 Usage
Uses
Used in Pharmaceutical Industry:
(E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide is used as a potential pharmaceutical agent for its structural features and the presence of both an amide and amino groups, which may allow for various interactions with biological systems. (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide's specific application within the pharmaceutical industry would require further research and testing to determine its efficacy and safety.
Check Digit Verification of cas no
The CAS Registry Mumber 2135696-72-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,3,5,6,9 and 6 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2135696-72:
(9*2)+(8*1)+(7*3)+(6*5)+(5*6)+(4*9)+(3*6)+(2*7)+(1*2)=177
177 % 10 = 7
So 2135696-72-7 is a valid CAS Registry Number.
2135696-72-7Relevant academic research and scientific papers
USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
-
Paragraph 0049; 0061-0063, (2021/08/06)
Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti- HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti -HER2/HER3 antibodies.
HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
-
Paragraph 0301-0303, (2020/11/03)
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
